Skip to content

Oxford Cannabinoid Technologies

Unlocking the potential of medical cannabis

Type: Company Creation / Significant Minority
Sector: Life Sciences

Changes in law have resulted in the medical cannabis market opening across the world. However, there remains a gap in cannabinoid drug development companies, focused on understanding the molecular actions of cannabinoids in detail and how they can improve the quality of life for millions of patients.

KCP founded OCT in 2017 after over a year of discussions with Oxford University (its lead research partner). With a focus on oncology, pain, immunology and neurology, OCT vision is to become a global leader in developing cannabinoid-based prescription medicine, working with world-class partners on research and drug development.

OCT now has lead compound under development for a range of indications, an expanding library of IP library, and has now completed several rounds of funding.

If you would like to know more about our work with Oxford Cannabinoid Technologies, please contact us.